SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Baert Filip J.)
 

Sökning: WFRF:(Baert Filip J.) > (2022) > Pharmacokinetic-Pha...

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease : Posthoc Analysis of the LOVE-CD Study

Hanzel, Jurij (författare)
Univ Ljubljana, Univ Med Ctr Ljubljana, Fac Med, Ljubljana, Slovenia.;Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands.
Dreesen, Erwin (författare)
Uppsala universitet,Institutionen för farmaci,Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
Vermeire, Severine (författare)
Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium.
visa fler...
Lowenberg, Mark (författare)
Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands.
Hoentjen, Frank (författare)
Radboud UMC, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands.
Bossuyt, Peter (författare)
Imelda Gen Hosp, Imelda GI Clin Res Ctr, Bonheiden, Belgium.
Clasquin, Esme (författare)
Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands.
Baert, Filip J. (författare)
AZ Delta, Div Gastroenterol, Roeselare, Belgium.
D'Haens, Geert R. (författare)
Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands.
Mathot, Ron (författare)
Amsterdam UMC, Dept Hosp Pharm Clin Pharmacol, Amsterdam, Netherlands.
visa färre...
Univ Ljubljana, Univ Med Ctr Ljubljana, Fac Med, Ljubljana, Slovenia;Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands. Institutionen för farmaci (creator_code:org_t)
2021-06-17
2022
Engelska.
Ingår i: Inflammatory Bowel Diseases. - : Oxford University Press (OUP). - 1078-0998 .- 1536-4844. ; 28:5, s. 689-699
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BackgroundHigher serum concentrations of vedolizumab have been associated with improved outcomes in inflammatory bowel disease. It is unclear how vedolizumab exposure is linked to endoscopic remission in Crohn disease (CD). We aimed to develop a pharmacokinetic-pharmacodynamic model linking vedolizumab exposure to endoscopic remission in CD.MethodsData were obtained from the first 110 patients participating in a phase 4 prospective multicenter trial (LOVE-CD; ClinicalTrials.gov identifier: NCT02646683), where vedolizumab was dosed at 300 mg every 8 weeks and serum concentrations and antibodies to vedolizumab were measured before each infusion. Concentration-time profiles were described by a 2-compartment model with parallel linear and nonlinear elimination. A first-order discrete-time Markov model was used to describe the relationship between pharmacokinetic exposure metrics and the probability of endoscopic remission (Simple Endoscopic Score for CD < 4).ResultsLinear clearance was 0.215 L/d, and the volume of distribution of the central compartment was 4.92 L. Linear clearance was higher and vedolizumab exposure was lower in patients with lower serum albumin concentrations, in the presence of antibodies to vedolizumab, and in patients with previous exposure to other biologic therapy. A week 22 vedolizumab concentration of 20.0 mg/L was predicted to yield a 35% probability of achieving endoscopic remission at week 26. Model-based simulations suggested that endoscopic remission rates of 46.5% or 40.0% could be reached with every-4-weeks dosing in patients who were naive or previously exposed to biologic therapy, respectively.ConclusionsModel-informed dosing of vedolizumab in CD provides a foundation for future research aiming to maximize endoscopic remission rates.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Nyckelord

therapeutic drug monitoring
exposure-response
pharmacometrics
inflammatory bowel disease

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy